



NOVAGALI P H A R M A

Dr. Ronald R. Buggage appointed as Chief Scientific Officer of Novagali Pharma

Evry (France), March 16th 2011: Novagali Pharma, a pharmaceutical company that develops innovative ophthalmic products, today announced the appointment of Dr. Ronald R. Buggage as Chief Scientific Officer.

Ronald Buggage is an ophthalmologist by training and has acquired solid university and industrial experience in strategic and operational activities related to the ophthalmic pharmaceutical development and marketing. He is joining Novagali Pharma as Chief Scientific Officer, and will head all Clinical, Regulatory and Research & Development activities.

He began his career as Staff Clinician and Director of the Ocular Immunology and Uveitis Program at the prestigious National Eye Institute of the National Institutes of Health in Bethesda, Maryland, where he led numerous clinical trials in subjects with retinal disease and was responsible for the education and clinical supervision of ophthalmologists in training.

In 2004, he joined Pfizer's laboratories, becoming Worldwide Medical Director for Research & Development. He notably led strategic plans aimed at strengthening Pfizer's position in retinal diseases.

In 2008, Dr Buggage joined the Novartis group. As New Product Executive Medical Director within the Neuroscience and Ophthalmology Franchise, he was responsible for defining and executing the global development strategy for ophthalmic therapies within the perspective of their commercialisation.

Ronald R. Buggage, appointed Chief Scientific Officer at Novagali Pharma, states: *"I was attracted by Novagali Pharma, the competence of its teams, the wealth of its already well-advanced and promising product portfolio and the development potential of its unique technological platforms. Novagali Pharma is an exciting company dedicated to improving the life of patients with ophthalmic diseases through innovation, and I am delighted to now have the means of contributing to its expansion."*

Jérôme Martinez, Chairman and CEO of Novagali Pharma, concludes: *"We are very proud and very happy that Ronald has chosen to join Novagali Pharma. His advanced specialised skill and experience in ophthalmology, in terms of Research, product development strategy and registering products with the relevant authorities will be major advantages for the successful development of Novagali Pharma's product portfolio."*


About NOVAGALI Pharma (www.novagali.com)

Founded in 2000, Novagali Pharma SA is a pharmaceutical company that develops ophthalmic innovative products for all segments of the eye. Thanks to its three proprietary technology platforms, the Company has an advanced portfolio of highly innovative products, one of which is already on sale and two of which are undergoing phase III clinical trials.

In 2009, Frost & Sullivan recognised Novagali with the Award for Industry Innovation & Advancement of the Year, for its proprietary emulsion technology platforms, and Siemens awarded the company the "Health Award" Grand Prix de l'Innovation for Novasorb®.

In April 2010, Novagali Pharma and its partners in the Vitrena project obtained €9.4 million in funding from Oséo for this diabetic retinopathy project. Novagali Pharma carried out a successful IPO in July 2010 enabling the Company to raise €22 million.





Contacts

Novagali
Geneviève Garrigos
VP HR & Communication
Tel: +33 (0)6 65 54 60 19

NewCap.
Financial communication
Axelle Vuillermet / Emmanuel Huynh
Tel: +33 (0)1 44 71 94 93
Email: novagali@newcap.fr

Novagali Pharma is listed on NYSE Euronext Paris - Compartment C
ISIN code: FR0010915553 - Ticker: NOVA

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risques") section of the Document de Base filed with the AMF, which is available on the AMF website (<http://www.amf-france.org>) or on Novagali Pharma's website (www.novagali.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Novagali Pharma in any country.